Actively Recruiting

Age: 18Years +
All Genders
NCT06390306

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Led by Peking University People's Hospital · Updated on 2025-06-03

30

Participants Needed

15

Research Sites

178 weeks

Total Duration

On this page

Sponsors

P

Peking University People's Hospital

Lead Sponsor

U

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a prospective multi-center study to investigate efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) combined with azacitidine and B-cell lymphoma-2 (Bcl-2) inhibitor in patients with myeloid blast phase chronic myeloid leukemia (CML-MBP).

CONDITIONS

Official Title

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Philadelphia chromosome (Ph)-positive or BCR::ABL-positive chronic myeloid leukemia
  • Serum creatinine level less than or equal to 1.5 times the upper limit of normal (ULN) or creatinine clearance at least 50 mL/min if serum creatinine is above 1.5 times ULN
  • Serum total bilirubin less than or equal to 1.5 times ULN
  • Aspartate aminotransferase and alanine aminotransferase levels less than or equal to 2.5 times ULN
  • Amylase level less than or equal to 1.5 times ULN
  • Lipase level less than or equal to 1.5 times ULN
  • Ejection fraction greater than 50%
  • Corrected QT interval on electrocardiogram less than or equal to 450 ms in men or 470 ms in women
Not Eligible

You will not qualify if you...

  • Having other diseases requiring treatments that might interact with third-generation TKIs
  • Diagnosis of other primary cancers
  • History of allogeneic hematopoietic stem cell transplant
  • Having only extramedullary disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Peking university people's hospital

Beijing, Beijing Municipality, China, 100044

Actively Recruiting

2

Beijing Lu Daopei Hospital

Beijing, China

Actively Recruiting

3

Chuiyangliu hospital affiliated to tsinghua university

Beijing, China

Not Yet Recruiting

4

Sichuan Provincial People's Hospital

Chengdu, China

Not Yet Recruiting

5

Nanfang Hospital, Southern Medical University

Guangdong, China

Not Yet Recruiting

6

The First Affiliated Hospital of Kunming Medical University

Kunming, China

Not Yet Recruiting

7

The First Affiliated Hospital of Nanjing Medical University

Nanjing, China

Actively Recruiting

8

The First Affiliated Hospital of Guangxi Medical University

Nanning, China

Actively Recruiting

9

Nanyang Central Hospital

Nanyang, China

Actively Recruiting

10

Ningbo Medical Center Lihuili Hospital

Ningbo, China

Actively Recruiting

11

Qilu Hospital of Shandong University

Qilu, China

Not Yet Recruiting

12

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Tianjin, China

Not Yet Recruiting

13

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Henan Cancer Hospital

Wuhan, China

Not Yet Recruiting

14

Xi'an International Medical Center Hospital

Xi'an, China

Actively Recruiting

15

The First Affiliated Hospital, Zhejiang University School of Medicine

Zhejiang, China

Actively Recruiting

Loading map...

Research Team

Q

Qian Jiang, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here